X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Morningside Venture
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2021
Details:
Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BOS-580
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Boston Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2020
Details:
Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CM5480
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: CalciMedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2020
Details:
CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
